714-X (Naessens)

This is a historical account. 714-X has no legitimate use by a psychotherapist. Nothing here endorses it or describes it as a treatment for cancer or any other disease. The psychotherapist's own work, with clients and families who are considering it, using it or living with the aftermath, is in section 5.

1. What it was

Version followed: 714-X as described by the U.S. National Cancer Institute PDQ summary (last updated 2018 and no longer updated), the 1998 CMAJ review for the Canadian Breast Cancer Research Initiative, Quackwatch's 2002 account, and Québec press reports at the developer's death (2018). Manufacturer claims are given only as these sources report them.

Who, where, when

714-X (also written 714X) was developed by Gaston Naessens, a French-born researcher. He worked for over 30 years from a privately funded laboratory in Québec. [source: Kaegi 1998, CMAJ; NCI PDQ]
The name is a personal tribute. 7 and 14 are the alphabet positions of his initials, and X (the 24th letter) stands for his birth year, 1924. [source: Kaegi 1998]
France, before 714-X. In 1956 a French court convicted him of the illegal practice of medicine and fined him, and afterwards his treatment had to be given by a doctor. [source: Quackwatch] He promoted two earlier products:
- "G.N. 24", which a Swiss pharmacist found to contain mineral salts and methylene blue. [source: Quackwatch]
- "Anablast", which drew worldwide attention in 1963 when it was given to a young child. [source: Quackwatch] In 1964 Professor Pierre Denoix of the Institut Gustave-Roussy tested Anablast and found it had no therapeutic value. In every allegedly successful case Denoix examined, the patient had first received standard treatment. Naessens was then indicted again for illegal practice of medicine and pharmacy. [source: Quackwatch, citing the American Cancer Society's 1967 report in CA: A Cancer Journal for Clinicians 17:86–87]
Québec. He settled in Québec, then at Rock Forest near Sherbrooke, where he opened a laboratory beside his home. [source: La Tribune 2018] Sources differ on the date: La Tribune says the mid-1960s, Quackwatch says the early 1970s [uncertain]. The product appears to have been developed in the 1960s. [source: NCI PDQ]
Distributor. CERBE Distribution Inc., Rock Forest, Québec, marketed it worldwide and supplied the technical data. [source: NCI PDQ; Kaegi 1998]
Teaching and promotion. He and his wife founded the International Academy of Somatidian Orthobiology in 1995. It ran seminars, private courses and public conferences. [source: Quackwatch]
1989 arrest and trial. Police arrested him at his laboratory on 30 May 1989, and the arrest was filmed live on television. He was charged with criminal negligence and fraud for giving a patient false hope of a cure, and was acquitted after trial at the Sherbrooke courthouse. [source: La Tribune 2018; La Presse 2018] Sources describe the charges differently: Quackwatch describes the trial as one for practising medicine without a licence, ending in a jury acquittal. [source: Quackwatch]
He died at his home in Sherbrooke in February 2018, aged 94. His widow, also a biologist, said she would continue the laboratory's work and promote 714-X "in collaboration with medicine" (paraphrase). [source: La Tribune 2018; La Presse 2018]

The stated rationale

Somatoscope. He said he built a high-magnification dark-field microscope, the "somatoscope", to view fresh, unstained blood. Quackwatch reports his claim that it magnified up to 30,000 times. [source: Kaegi 1998; NCI PDQ; Quackwatch]
Somatids. He claimed the somatoscope showed tiny living particles, "somatids". In health they were said to run a 3-form "microcycle". Stress or other triggers were said to switch them into a 16-form "macrocycle" that releases growth substances ("trephones") which disrupt cells and immunity and drive cancer. [source: Kaegi 1998] Peer-reviewed literature does not support the somatid theory. Medline and a standard medical dictionary have no entry for the term. [source: NCI PDQ; Quackwatch]
The "nitrogen trap". Developers claimed that cancer cells take nitrogen from the body and release an immune-suppressing "cocancerogenic K factor" (CKF). They said camphor is drawn to cancer cells, and 714-X carries nitrogen to them so that they stop draining it from normal cells. The product was also said to make lymph more "fluid" and to "protect, stabilise and reactivate" the immune system. [source: NCI PDQ; Kaegi 1998] None of this is supported by peer-reviewed evidence. [source: NCI PDQ]
What it contained. The developers described a camphor compound chemically modified with nitrogen or ammonium groups, in a saline solution with ammonium salts and ethanol. [source: Kaegi 1998; NCI PDQ] An FDA analysis of a sample found it was almost all water with nitrate and ammonium salts, and camphor only at trace level. The manufacturer listed trace metals, including aluminium, arsenic, lead and mercury. [source: Quackwatch] Production was unregulated, with no guarantee of consistent quality. [source: NCI PDQ]

How it was sold to patients and referrers

Claims. It was promoted as restoring immunity and reversing disease. Claimed effects were shrinking tumours, better appetite and better wellbeing. [source: Kaegi 1998] Claims went beyond cancer to multiple sclerosis, fibromyalgia, AIDS and other "degenerative diseases". [source: Quackwatch; Kaegi 1998] Later wording said it "supports the natural defenses" through "deep cellular cleansing". [source: Quackwatch, quoting the manufacturer]
Framing. It was described as non-toxic and compatible with conventional care, but said to work best in patients who had not had chemotherapy or radiotherapy, so patients were urged to start early. [source: Kaegi 1998] Naessens said he was blacklisted because his product threatened the pharmaceutical industry. [source: La Tribune 2018]
Testimonials. Patient testimonials appeared in newspapers, books and other non-medical outlets. [source: NCI PDQ; Kaegi 1998] In 1998 use was growing, especially among people with breast and prostate cancer. [source: Kaegi 1998]

Regulatory status

Canada. It was never approved. [source: La Presse 2018; La Tribune 2018] It was available only on compassionate grounds, requested by a physician for a named patient through Health Canada's Emergency Drug Release Programme, later the Special Access Programme. [source: Kaegi 1998; NCI PDQ; Quackwatch] Access through this route does not mean government approval. [source: Quackwatch] A Health Canada policy decision of 23 January 2004 restricted special access: new patients were unlikely to be authorised without significant new evidence, patients already on it had a one-year transition, and future use was tied to a manufacturer-sponsored clinical trial; Health Canada's reviews found no credible scientific basis for its use. Four patients sought judicial review, heard together in the Federal Court (Delisle v. Canada (Attorney General), 2006 FC 933, 28 July 2006). [source: Federal Court, 2006 FC 933] A secondary account reports that the ruling restored conditional access and that Health Canada told the manufacturer in 2004 to remove references to the product from its website [uncertain: secondary, unverified].
United States. The FDA has not approved it for any condition and has an import ban in place (Import Alert). [source: NCI PDQ; Quackwatch]
Evidence status (one line). There are no peer-reviewed human studies of any design. The few animal studies, in rat lymphosarcoma and dog and cow lymphoma, found no benefit. The NCI board states its use for cancer "cannot be recommended" outside well-designed trials. [source: NCI PDQ; Kaegi 1998]

2. What was actually done

A typical course, as the review and regulatory literature describe it. Amounts, volumes and exact schedules are deliberately omitted.

Finding it. Patients usually heard of 714-X through testimonials, books, seminars, the somatid lectures or word of mouth, often at diagnosis or after a recurrence. [source: Kaegi 1998; NCI PDQ; Quackwatch]
"Assessment". Advocates offered live-blood examination with the somatoscope or dark-field microscopy, reading somatid forms as signs of disease. One U.S. distributor claimed this blood test could predict cancer and immune disorders up to two years in advance, a claim with no supporting evidence. [source: Quackwatch] There was no selection by cancer type or stage. The claimed range covered many cancers and non-cancer illnesses. [source: Kaegi 1998; Quackwatch]
Getting the product and consent. In Canada a licensed physician asked Health Canada's emergency or special-access programme to release it for a specific patient, and CERBE supplied it. [source: Kaegi 1998; Quackwatch] Patients chose it on the strength of claims and testimonials, not trial data, because no human efficacy data existed. [source: NCI PDQ] The message that it worked best before chemotherapy or radiotherapy put pressure on timing: start early, before standard treatment. [source: Kaegi 1998] Whether patients were told plainly that no human evidence existed is not documented in the cited sources [uncertain].
Training lay people to inject. The usual route was injection near the lymph nodes of the groin, a route health workers needed special instruction for. CERBE supplied videos and printed materials for patients and caregivers. [source: Kaegi 1998; Quackwatch] Treatment was therefore often given at home rather than in a clinical setting [synthesis, inferred from the caregiver materials]. Intravenous and oral use were not recommended. [source: Kaegi 1998; NCI PDQ]
Cycles. Injections were given repeatedly in courses called "cycles", separated by rest periods. Repeated cycles were standard, more were urged for advanced disease, and "prevention" courses were offered to people without cancer. [source: Kaegi 1998; Quackwatch; NCI PDQ]
Nebuliser variant. Later, distributors offered a nasal nebuliser form for lung, oral and head-and-upper-body cancers, and for follow-up. [source: Kaegi 1998; NCI PDQ; Quackwatch]
Rules during treatment. Patients were told to avoid alcohol, vitamin B12 and vitamin E supplements, and shark or bovine cartilage. [source: Kaegi 1998; NCI PDQ]
Judging "progress". Progress was judged by testimonials and how the person felt (appetite, wellbeing), by claimed tumour shrinkage, and in some settings by repeat live-blood examinations. [source: Kaegi 1998; Quackwatch] Outcomes were not systematically followed up, and the producers said they could not collect long-term data. [source: NCI PDQ; Kaegi 1998]
Non-response and criticism. When animal studies found no effect, Naessens said the "real" 714-X had not been used. [source: Kaegi 1998] Opposition was put down to the pharmaceutical industry. [source: La Tribune 2018] Patients whose disease progressed could be advised to have more cycles [synthesis, inferred from the cycle recommendations above].
Supply outside Canada. In the U.S., distributors imported and resold it. In 1996 one importer-distributor was convicted on 18 counts of selling an unapproved drug and received a one-year prison sentence. His conviction was upheld on appeal. [source: Quackwatch] It was also sold in Mexico and Western Europe. [source: Kaegi 1998]

3. How it caused harm

Delay or replacement of effective cancer treatment (the main harm). The "start before chemotherapy or radiotherapy" message and the immune-restoration story both steered people away from timely standard treatment. [source: Kaegi 1998] Large-scale data show what this costs. In U.S. National Cancer Database patients (Johnson et al., JNCI, doi 10.1093/jnci/djx145), people who used alternative medicine instead of conventional treatment had a higher risk of death. The excess was clear for breast, lung and colorectal cancer. [source: Futurity summary of Johnson et al.] This finding is about alternative medicine in general, not 714-X specifically. No outcome series for 714-X users exists. [source: NCI PDQ]
False hope, and fraud as charged. The 1989 Québec charges were about giving a patient false hope of a cure. They ended in acquittal, so no criminal finding was made. [source: La Tribune 2018; La Presse 2018] The earlier French investigation found that apparent successes of his previous product followed standard treatment, which shows how credit can be wrongly given to an alternative product. [source: Quackwatch]
Deaths. One death linked to the 1989 case is reported only by a secondary source [uncertain: secondary, unverified]. No series of documented 714-X deaths is reported in the cited regulatory or peer-reviewed sources [uncertain].
Physical effects. The only reported side effects were redness, tenderness and swelling at injection sites. [source: NCI PDQ; Kaegi 1998] The 1998 review found no published reports of infection. [source: Kaegi 1998] Unregulated manufacture with no quality guarantee, and trace metals in the manufacturer's own list, are untested risks. [source: NCI PDQ; Quackwatch] Camphor taken internally can be seriously toxic, but this is a general fact about camphor, not a documented 714-X injury. [source: Kaegi 1998]
Interference with treatment advice. Telling patients to avoid certain vitamins and cartilage products during cycles added rules outside medical oversight [synthesis]. Wider reviews note that alternative products can interfere with conventional treatment. [source: Cancer Research UK]
Financial harm. The cited sources do not give 714-X prices [uncertain]. Alternative cancer regimes generally involve large monthly costs plus travel. [source: Cancer Research UK] Repeated cycles, "prevention" courses, live-blood tests and seminars were all sources of income [synthesis].
Psychological harm [synthesis, from clinical experience patterns; not documented for 714-X specifically]:
- The somatid story said stress triggers the disease cycle. This can leave people blaming themselves for their cancer or its progression.
- Disappointment when the disease progresses.
- Survivors' and families' regret and guilt over delayed treatment.
- Family conflict over choices.
- Caregivers who did the daily injections can carry particular grief and responsibility.
Legal harm to sellers. Importing and distributing it in the U.S. led to criminal conviction. [source: Quackwatch]
Who was most at risk [synthesis, from the sources above]:
- People with early, curable cancers, for whom delay costs most.
- People with breast and prostate cancer, among whom use was growing. [source: Kaegi 1998]
- People told to start before standard therapy.
- People with advanced disease desperate for hope. [source: Cancer Research UK on vulnerability]
- People who distrust medicine or the pharmaceutical industry.
- Children and dependent adults whose care decisions are made by others.

4. Recognising it today

Names and terms that signal 714-X or its theory

Product names: "714-X" or "714X"; CERBE; "Naessens".
Theory and training: "somatids", "somatidian orthobiology", the International Academy of Somatidian Orthobiology. [source: Quackwatch]
Diagnostic claims: the "somatoscope"; "16-form macrocycle"; "trephones". [source: Kaegi 1998]
Mechanism claims: "cocancerogenic K factor" (CKF), "nitrogen trap", "lymph fluidity". [source: NCI PDQ]
Marketing phrases: "deep cellular cleansing"; "protects, stabilises and reactivates the immune system". [source: Quackwatch; NCI PDQ]

Phrases and rationales clients may repeat (illustrative paraphrases of the claims in section 1)

"It doesn't attack the cancer, it lets my own immune system do it."
"It works best if I haven't had chemo or radiation yet, so I have to start now." This is the most dangerous rationale because it pushes for delay.
"Health Canada lets doctors get it, so it must be approved." Special-access release is not approval. [source: Quackwatch]
"The drug companies suppressed it." [source: La Tribune 2018]
"It's non-toxic, so there's nothing to lose." This leaves out the cost of delay. [source: Kaegi 1998; Cancer Research UK]
"A blood test under a special microscope showed my somatids in the disease cycle." Live-blood or dark-field microscopy readings are offered as diagnosis. [source: Quackwatch] See the guides on live-blood analysis where present.
"It's a prevention course." [source: Quackwatch]

Rebrandings and neighbours [synthesis]

The same pattern shows up across the alternative cancer regimes in this family: a lone discoverer, a microscopic "hidden cause", immune or "terrain" restoration, "non-toxic" claims, testimonials, an industry-suppression story and courses for practitioners.
Alternative cancer clinics sell package programmes, often abroad. [source: Cancer Research UK]

Red flags in a colleague's or service's practice [synthesis, informed by Cancer Research UK warning signs]

Any psychotherapist, coach or wellness provider who recommends, sells, supplies or helps arrange injections of 714-X or similar products.
Referring clients to somatid or live-blood testing.
Teaching that stress causes cancer through a "cycle" that therapy can reverse.
Framing psychological work as an alternative to oncology rather than alongside it.
Receiving referral fees or course income linked to such products.
Discouraging clients from telling their oncologist.
Claims of cure, or of working where conventional treatment cannot. [source: Cancer Research UK]

How legitimate practice differs [synthesis unless cited]

Integrative oncology (entry 172) is complementary to standard treatment, never instead of it. It uses supportive therapies for symptoms and quality of life, and does not claim to treat the cancer.
Psycho-oncology addresses distress, coping, meaning and decisions. It does not promise disease control.
Real special-access use is physician-led for a named patient when no marketed option exists. It is not an endorsement. [source: Quackwatch]
Clinical trials are the legitimate route to unproven agents. The NCI board's position is that 714-X should be used only within well-designed trials. [source: NCI PDQ]

5. What to do instead and how to help those harmed

Recommended alternatives (by name)

Standard oncology care, planned with the treating team. [source: Cancer Research UK: talk to your cancer doctor about any therapy you are considering]
Clinical trials, the only legitimate route to unproven agents. [source: NCI PDQ; Cancer Research UK]
Specialist palliative care, alongside treatment and not only at the end of life [synthesis].
Integrative oncology (entry 172): evidence-informed supportive therapies alongside treatment.
Psycho-oncology support [synthesis]:
- for distress and decision stress;
- meaning-centred and dignity-focused work for advanced disease;
- grief therapy for bereaved families.
Patient support lines, for example Cancer Research UK's nurse helpline and Cancer Chat forum in the UK. [source: Cancer Research UK]

The psychotherapist's role and limits [synthesis]

You never recommend, supply, sell, inject, arrange or monitor 714-X or any alternative product.
You never advise starting, stopping or changing any medicine, supplement or remedy. Route those questions to the oncologist, GP or pharmacist.
You do not judge the client's capacity for medical decisions. That belongs to the treating physician, though you can share relevant observations with consent.
Your work is to keep communication open, help the client think clearly in line with their own values, coordinate care, attend to risk, and support grief and repair.
Professional ethics codes require competence, avoiding exploitation and managing conflicts of interest. Check your own code [synthesis].

5.1 Asking routinely and without judgement

Purpose: Find out about alternative product use early, while there is still time to coordinate. Clients often hide use from clinicians they expect to disapprove [synthesis].
Steps:
1. Ask every client with cancer, or caring for someone with cancer, about all treatments, products, tests, clinics and courses, conventional or not.
2. Use open, neutral wording and normalise the question.
3. Record what is used, who supplies it, who gives it (self, family, practitioner), any live-blood or other tests, costs, and whether the oncologist knows.
4. Note any timing pressure, such as being told to start before chemotherapy or radiotherapy.
Example language (illustrative): "Many people look into all sorts of options after a diagnosis. Are you using or considering anything besides what your cancer team has planned: injections, supplements, clinics, special blood tests?"
Watch for:
- Vague answers, or "my doctor doesn't need to know".
- Any plan to delay surgery, chemotherapy or radiotherapy.
- A family member doing injections at home.
- It is working when the client volunteers details and updates without fear of judgement.

5.2 Exploring meaning, hopes and the explanatory model

Purpose: Understand what 714-X means to the client. It may stand for control, hope, a gentler path, distrust of medicine, belonging to a community, or loyalty to someone who recommended it. [synthesis; Cancer Research UK notes vulnerability and the wish to try anything]
Steps:
1. Ask how they came across it and what drew them.
2. Elicit their model of the illness, including any belief that stress or "immune collapse" caused it, and any self-blame that goes with it.
3. Reflect the underlying need (hope, agency, fewer side effects, being heard) separately from the product.
4. Explore fears about conventional treatment: side effects, past bad experiences, loss of control.
5. Look for other ways to meet those needs: symptom control, a second oncology opinion, palliative care, supportive therapies, practical help.
Example language (illustrative): "What does this treatment offer you that the hospital plan doesn't?" "If it worked exactly as you hope, what would be different for you and your family?" "Some explanations put the cause of cancer down to stress. How do you understand why this happened to you?"
Watch for:
- Self-blame and guilt.
- Fear of chemotherapy driven by a past experience, which may respond to specific information from the team.
- Grandiose hope used to defend against despair. Go gently and do not strip away hope.
- It is working when the client can name their needs apart from the product.

5.3 Supporting an informed, values-based decision (autonomy-respecting)

Purpose: Help the client make their own decision with full information and without coercion from you, the family or sellers. [synthesis]
Steps:
1. Clarify what decision is actually being made: alongside treatment, instead of it, or delaying it. These carry very different risks. [source: Futurity/Johnson et al.: substitution is linked to worse survival]
2. Help the client list the questions to take to the oncologist:
  - What is the expected benefit of standard treatment for my cancer and stage?
  - What happens if I delay?
  - Could this product interfere with my treatment?
  - Are there trials I am eligible for? [source: Cancer Research UK]
3. Help them look at the evidence in plain terms. The cancer agency position is that no human studies exist and the product is not approved. Share the agency summary rather than your own opinion. [source: NCI PDQ]
4. Do values clarification: what matters most (time, function, being at home, avoiding side effects, the children).
5. Respect the decision once it is informed, and keep the door open to change.
Example language (illustrative): "I'm not here to choose for you. I want to make sure you have what you need to choose. Would it help to write down the questions you want your oncologist to answer before you decide anything about timing?"
Watch for:
- The "start before chemo" deadline. Name the urgency as the seller's claim and slow the decision down.
- Pressure from relatives or a seller.
- Your own pull to argue or rescue. A therapist who argues can push the client towards the seller [synthesis].
- It is working when the client takes questions to the team and reports their answers.

5.4 Coordinating with the oncologist, GP, pharmacist and palliative team

Purpose: Make sure the treating team knows what is being used and can advise on interactions, delay and symptoms. [source: Cancer Research UK]
Steps:
1. Get written consent covering what you will share and with whom.
2. Encourage the client to tell their oncologist themselves. Offer to rehearse the conversation or to attend.
3. With consent, tell the team what you know: the product, how it is given, who supplies it, and any plan to delay treatment.
4. Refer any medicine or supplement question to the prescriber or pharmacist.
5. Offer an early palliative-care referral where appropriate.
6. Document all contacts.
Example language (illustrative): "Your oncologist can only look after you safely if they know everything you're taking. Would you like to practise how you'll tell them, or shall we call them together?"
Watch for:
- Fear that the team will drop the client if they find out.
- Injection-site redness, swelling or tenderness, or any sign of infection: refer for medical review [source: NCI PDQ on local reactions; infection referral is synthesis].
- It is working when the team is informed and the client stays engaged with them.

5.5 Responding to delay or refusal of effective treatment

Purpose: Respond when the client plans to delay or replace standard treatment. This is the main route to harm. [source: Kaegi 1998; Futurity/Johnson et al.]
Steps:
1. Check what they understand: what the oncologist said about curability and the effect of delay.
2. Ask whether a time-limited plan with medical review would be acceptable, for example agreeing a review date with the team. Keep it free of any suggestion that you endorse the product [synthesis].
3. Make sure the team knows about the planned delay (with consent).
4. Respect an informed adult's right to refuse. Keep the relationship going so the client can return to treatment without losing face.
5. If capacity seems impaired (delirium, severe depression, psychosis), raise it with the physician.
6. Assess for depression and suicidal thinking using standard practice. Refusing treatment can sometimes express hopelessness.
Example language (illustrative): "If you decide to wait, can we agree what would tell you it's time to go back to the team, and make sure they know your plan?"
Watch for:
- Symptoms getting worse while the client is told it is "detox" or "the immune system working" [synthesis].
- Shame that stops them returning.
- It is working when the door back to treatment stays open and is used.

5.6 Family work and conflict

Purpose: Families often split. One member champions the alternative, others push for standard treatment, and a carer may be the one giving the daily injections. [source: Kaegi 1998 on caregiver instruction materials; family dynamics are synthesis]
Steps:
1. With the patient's consent, meet the family. Confirm that the patient is the decision-maker if they are an adult with capacity.
2. Let each person say what they fear and hope for, without debating the product.
3. Separate the shared goal (the patient's wellbeing) from the disagreement about means.
4. Check the carer's burden. Giving injections at home carries responsibility and later grief.
5. Agree how the family will support whatever informed choice is made, and how disagreements will be handled.
Example language (illustrative): "Everyone here wants the same thing for your mother. The fight is about how. Can each of you say what you're most afraid of?"
Watch for:
- Coercion in either direction.
- A relative controlling information or money.
- Carer exhaustion.
- Children drawn into the conflict.

5.7 Grief, regret and guilt after choosing 714-X

Purpose: Help patients whose disease progressed, and bereaved families, with regret ("we lost time"), self-blame, anger at sellers or at themselves, and conflict over who decided. [synthesis]
Steps:
1. Assess grief, depression, suicidal thinking and trauma symptoms using standard tools and practice.
2. Give space to anger and regret without confirming or denying blame.
3. Work on hindsight bias: decisions were made with the information, fear and hope available at the time.
4. Address the stress-caused-cancer idea from the somatid story, which can drive self-blame. [source: Kaegi 1998 for the theory; the clinical response is synthesis]
5. For carers who did the injections, explore their sense of responsibility.
6. Where the person wants it, support meaning-making and repair between family members.
7. Refer to bereavement services as needed.
Example language (illustrative): "You chose with the hope and the information you had then. Looking back with what you know now is a different position. Can we make room for both the regret and the love behind that choice?"
Watch for:
- Complicated grief.
- Suicidal thinking.
- Persistent family blame.
- Rage that turns into seeking another unproven product.

5.8 Financial harm and exploitation

Purpose: Recognise and respond to spending on repeated cycles, tests, courses, clinics and travel. [source: Cancer Research UK on costs; 714-X-specific costs uncertain]
Steps:
1. Ask about money spent and committed, loans, fundraising or crowdfunding, and pressure to buy more cycles.
2. Look out for dependent or older adults being pressured by relatives or sellers.
3. Point the client to financial advice and consumer-protection routes.
4. Consider reporting (5.10).
Example language (illustrative): "How is the cost of all this sitting with you and the family? Is anyone pressing you to buy more?"
Watch for:
- Debt.
- Secrecy.
- A seller who is also a relative or a friend in the client's community.

5.9 Safeguarding

Purpose: Protect children and adults at risk. [synthesis; follow your local safeguarding procedures]
Steps:
1. If a child with cancer is being given 714-X instead of treatment, or is having treatment withheld, follow your child-protection procedures. Medical neglect is a safeguarding matter. Consult your designated safeguarding lead and the child's medical team.
2. Consider the child's assent and what they understand, in age-appropriate terms.
3. For adults at risk, such as those with cognitive impairment or under the control of others, follow adult-safeguarding routes.
4. Document your concerns, actions and consultations.
Example language (illustrative): "Because this involves a child's medical care, I have a duty to talk with the child's doctors. I'd rather do that with you than around you."
Watch for:
- Missed oncology appointments.
- A child doing poorly while the family says the treatment "is working".

5.10 Reporting

Purpose: Use the regulatory and professional routes for adverse effects, illegal sale and misleading claims. [synthesis on when to report]
Steps:
1. Canada:
  - Adverse reactions go to Health Canada through MedEffect Canada.
  - Complaints about health products go to Health Canada's complaint line or online form.
  - Authorised products carry a DIN, DIN-HM or NPN on the label. [source: Health Canada advisory, archived 2015; check current contacts]
2. United States: 714-X is under an FDA import ban. Report sales or promotion to the FDA [source: NCI PDQ for the import ban; reporting channel uncertain].
3. Elsewhere: report to the national medicines regulator and the advertising regulator [synthesis].
4. Report a regulated health professional who supplies or promotes it to their licensing board [synthesis].
5. Get consent for any disclosure unless the law or a safeguarding duty overrides it.
Example language (illustrative): "You have the right to report what happened. Would you like help finding out how?"
Watch for:
- The client's wish not to report. Respect it unless a safeguarding duty applies.

Handling problems [synthesis throughout]

The client asks your opinion of 714-X. Be honest and brief. Point to the cancer-agency summary (no human studies, not approved) and return to their decision process. Example (illustrative): "The cancer agencies say there are no human studies and it isn't approved. What I care about most is that you decide with all the facts and with your team in the loop."
The client stops coming after you raise concerns. Write a short, warm note that leaves the door open. Avoid repeated persuasion.
A relative asks you to "talk sense into" the patient. Decline to act as anyone's agent. Offer a family meeting with the patient's consent (5.6).
The client wants you to tell the oncologist they are not using it. You cannot collude in deception. Explore the fear behind the request.
Your own anger or helplessness. Seek supervision, especially when a client's choice leads to decline.
The client asks you to help with injections or to store or obtain the product. Refuse clearly. It is outside your scope and may be unlawful.
A community or group presses the client to stay with it (testimonial networks, seminars). Explore the social costs of leaving and help the client find other supports.

Sources

Web sources:

Cited via the sources above:

American Cancer Society (1967). Unproven methods of cancer treatment: Naessens serum, or anablast. CA: A Cancer Journal for Clinicians 17:86–87.
Johnson SB, Park HS, Gross CP, Yu JB. Use of alternative medicine for cancer and its impact on survival. JNCI, doi 10.1093/jnci/djx145.

← Previous · XII-161High-dose IV vitamin C as alternative cancer treatment Next · XII-163 →Cantron and Protocel